Abstract
Introduction The effect of coding polymorphisms of the beta-2 adrenergic receptor gene (ADRB2) on functional properties of the receptor is well-established. We recently reported a genome-wide significant association between Thr164Ile and lung function, but the contribution of this variant to other traits remains unclear.
Methods To identify pleiotropic effects of ADRB2 Thr164Ile and other coding variants, we performed respiratory-focused and phenome-wide association studies in UK Biobank. In addition, we used available Olink proteomic data to characterise enriched pathways and upstream regulators of proteins associated with ADRB2 polymorphisms.
Results The minor allele of Thr164Ile was associated with reduced lung function, but not COPD or asthma defined using self-report and diagnostic codes in healthcare records. It was also associated with non-respiratory traits including increased eosinophil counts and blood lipid measurements, including increased cholesterol, reduced triglycerides and reduced apolipoprotein A. Proteins associated with Thr164Ile (P-value≤0.01) were enriched for various pathways, with the eosinophil-raising allele associated with reduced neutrophil degranulation, immunoregulatory interactions between a Lymphoid and a non-Lymphoid cells, TNF binding and DAP12 interactions, as well as activation of lipid metabolism pathways, including FXR/RXR activation and LXR/RXR activation. A gene-based analysis of rare, non-synonymous ADRB2 variants, identified a novel association with non-rheumatic pulmonary valve disorders, but no association with lung function.
Discussion In conclusion, the lung function-lowering allele of Thr164Ile is associated with traits and proteins indicative of a role in immune and lipid metabolism pathways, but not COPD or asthma. In contrast, ADRB2 rare coding variants are not associated with lung function.
Competing Interest Statement
I.P. Hall. reports previous funding from Boehringer Ingelheim, outside the submitted work. L.V. Wain, M.D. Tobin and R.J. Packer report collaborative research funding from GSK and Orion Pharma, outside of the submitted work. L.V. Wain reports consultancy for GSK, Boehringer Ingelheim and Galapagos and has funding from Roche outside the submitted work. K. Fawcett, N. Shrine, R. Hall and K. Coley report no competing interests.
Funding Statement
This study was supported by a Wellcome Trust Award WT225221/Z/22/Z. The study was partially supported by the NIHR Leicester Biomedical Research Centre and an NIHR Senior Investigator Award to M.D.T, and by an Asthma + Lung UK Career Development Award (AUK-CDA-2019-414) to K.A.F; views expressed are those of the author(s) and not necessarily those of the NHS, the NIHR or the Department of Health. The funders had no role in the design of the study.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The North West Multi-center Research Ethics Committee, the National Information Governance Board for Health and Social Care in England and Wales, and the Community Health Index Advisory Group in Scotland (http://www.ukbiobank.ac.uk/ethics/) gave ethical approval for this work.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability
All summary statistics produced in the present work are contained in the manuscript. Researchers can apply for access to individual-level data from UK Biobank.
